Background Obesity is a major public health problem in many poor countries where micronutrient deficiencies are prevalent. A partial meal replacement may be an effective strategy to decrease obesity and increase micronutrient intake in such populations. The objective was to evaluate the efficacy of a partial meal replacement with and without inulin on weight reduction, blood lipids and micronutrients intake in obese Mexican women. Methods In a randomized controlled clinical trial 144 women (18–50 y) with BMI ≥ 25 kg/m 2 , were allocated into one of the following treatments during 3 months: 1) Two doses/d of a partial meal replacement (PMR), 2) Two doses/d of PMR with inulin (PMR + I) , 3) Two doses/d of 5 g of inulin (INU) and 4) Control group (CON). All groups received a low calorie diet (LCD). Weight, height, hip and waist circumference were measured every 2 weeks and body composition, lipids and glucose concentration and nutrient intake were assessed at baseline and after 3 months. Results All groups significantly reduced weight, BMI, waist and hip circumference. Differences between groups were only observed in BMI and weight adjusted changes: At 45 days PMR group lost more weight than INU and CON groups by 0.9 and 1.2Kg, respectively. At 60 days, PMR + I and PMR groups lost more weight than in INU by 0.7 and 1Kg, respectively. Subjects in PMR, PMR + I and INU significantly decreased triglycerides. Energy intake was reduced in all groups. Fiber intake increased in PMR + I and INU groups. Some minerals and vitamins intakes were higher in PMR and PMR + I compared with INU and CON groups. Conclusion Inclusion of PMR with and without inulin to a LCD had no additional effect on weight reduction than a LCD alone but reduced triglycerides and improved intake of micronutrients during caloric restriction. PMR could be a good alternative for obese populations with micronutrient deficiencies. ClinicalTrials.Gov ID NCT01505023
Introduction:The complications of type 2 diabetes mellitus (T2DM), such as chronic kidney disease (CKD), are the second leading cause of death in Oxcutzcab municipality of Yacatan, Mexico. The objective of the study was to estimate the burden of chronic kidney disease in a sample of patients with T2DM from Oxcutzcab municipality of Yacatan, Mexico, region characterized by high amound of poverty and vulnerabidity.Methods: This is a descriptive study involving 108 adult patients between 26 and 79 years old with T2DM who attended the PROSPERA, social protection program under the direction of Ministry of Social Development of Mexico (88% female and 12% male). Weight, height, BMI, and years of post T2DM diagnosis were measured. Estimated glomerular filtration rate (eGFR) was calculated using the Cockcroft-Gault formula. Results:We found that 39.81% of participants had stage one kidney damage, 34.26% stage two, 24.07% stage three, one case of stage four, and one of stage five. BMI measurements indicated that 40.74% of participants were obese (≥30kg/m 2 ), 35.19% were overweight, and 1.85% were underweight. In terms of years since diagnosis, 37.04% of the participants were diagnosed five years ago and less, 29.63% of participants were diagnosed 6-10 years ago, 22.22% between 11-15 years ago, 8.33% between 16-20 years ago, and 2.78% of participants over 20 years ago. Conclusions:Most participants were in stages one to three of kidney damage, where the main objective of the medical team was medical treatment of T2DM and comorbidities, as well as nutritional support to prevent further complications. There was only one case in stage four and five each, where dialysis and kidney transplantation became necessary. Both cases presented had a history of T2DM for over 20 years. It is important to identify early kidney damage to improve quality of life, reduce the treatment costs, and lower mortality.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.